Liver Fibrosis Statistics in US 2026 | Symptoms, Prevention & Treatment

What Is Liver Fibrosis?

Liver fibrosis is one of those conditions that quietly destroys a vital organ long before most people even realize something is wrong. At its core, liver fibrosis is the accumulation of excessive scar tissue — primarily excess collagen — within the liver as a response to chronic injury or inflammation. When the liver sustains repeated damage over months or years, its natural repair mechanism kicks in, generating fibrous scar tissue to patch the injury. In healthy livers, this process is controlled and reversible. But in people with persistent liver damage — from metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), alcohol-related liver disease (ALD), chronic hepatitis B or C, or other causes — this scarring process becomes relentless, eventually distorting the liver’s architecture and replacing functional tissue with rigid, non-functioning fibrous bands. Left unchecked, liver fibrosis progresses to cirrhosis, the irreversible terminal stage of liver scarring, and from there to liver failure or hepatocellular carcinoma (HCC). What makes liver fibrosis particularly dangerous is how silently it advances — the vast majority of people with early-to-moderate fibrosis have no noticeable symptoms, making it one of the most underdiagnosed serious conditions in American healthcare.

The scale of liver fibrosis in the United States in 2026 is alarming by any measure. According to the most current federal health data — the CDC’s National Center for Health Statistics (NCHS) updated in February 2026 — chronic liver disease and cirrhosis claimed 52,274 lives in 2024, ranking as the 9th leading cause of death in the country, with a crude death rate of 15.4 deaths per 100,000 population. The underlying driver of this crisis is the epidemic of metabolic liver disease: the National Health and Nutrition Examination Survey (NHANES) 2017–2023 data, published in Hepatology in November 2025, found that 11.3% of U.S. adults — representing tens of millions of people — have clinically significant liver fibrosis, and that this proportion rose from 10.4% to 12.7% between the pre-pandemic and pandemic survey cycles. With obesity, type 2 diabetes, and metabolic syndrome continuing to rise across the American population, liver fibrosis in the US 2026 is on a trajectory that healthcare systems, policymakers, and patients urgently need to understand and address.

Key Interesting Facts About Liver Fibrosis in the US 2026

Before examining the full statistical breakdown of liver fibrosis in the United States 2026, it is worth pausing on some of the most striking verified facts drawn from U.S. government health agencies, peer-reviewed studies using CDC WONDER and NHANES data, and NIH-affiliated research published through 2025–2026.

Source: CDC/NCHS FastStats Chronic Liver Disease and Cirrhosis, last reviewed February 20, 2026; NHANES 2017–2023 data published in Hepatology, November 2025; NIH/NIDDK; CDC WONDER Mortality Database

These facts, taken together, reveal a public health emergency hiding in plain sight. The figure of 52,274 deaths in 2024 is striking on its own — but what makes it even more alarming is the evidence that these deaths represent a significant undercount of the true liver-related mortality burden, since many liver disease deaths are attributed to other causes like cardiovascular disease or diabetes on death certificates. The 11.3% fibrosis prevalence figure from NHANES 2017–2023, published in one of the most authoritative hepatology journals, is perhaps the single most important statistic in this entire picture: roughly 1 in 9 American adults currently has liver scarring significant enough to place them at elevated risk of cirrhosis, liver cancer, or liver failure. The fact that this number rose measurably during the COVID-19 pandemic — driven largely by increased alcohol consumption and metabolic deterioration — signals that liver fibrosis trends in the US are worsening, not stabilizing.

Liver Fibrosis Prevalence Statistics in the US 2026

Understanding how widespread liver fibrosis is in America 2026 requires examining data from multiple layers of the U.S. population. The most authoritative recent sources are the NHANES 2017–2023 analysis published in Hepatology (November 2025) by NIH/NIDDK researchers, and the CDC NCHS FastStats, last updated February 20, 2026.

Source: CDC/NCHS FastStats Chronic Liver Disease, last reviewed February 20, 2026; NHANES 2017–2023 published in Hepatology, Vol. 82(5), November 2025 (NIH/NIDDK funded); PMC systematic review and meta-analysis, 2024

The prevalence numbers here deserve careful unpacking. When NHANES data shows 11.3% of U.S. adults have clinically significant liver fibrosis, and that this percentage climbed from 10.4% to 12.7% across survey cycles, that represents a real and measurable increase in one of the most serious forms of chronic liver damage — not just a counting artifact or diagnostic shift. The 28.7% steatotic liver disease prevalence is the upstream driver of this fibrosis epidemic: nearly 3 in 10 American adults have excess liver fat detectable by imaging, placing them on a potential progression pathway toward inflammation, fibrosis, and cirrhosis over years or decades. The estimate of 112.8 million adults living with any chronic liver disease is a figure that should reframe how Americans think about liver health — this is not a niche condition affecting a small at-risk subgroup, but rather a condition that touches more than one-third of the entire adult population in some form.

Liver Fibrosis Mortality Statistics in the US 2026

The mortality data on liver fibrosis and cirrhosis in the United States 2026 is drawn directly from the CDC’s National Center for Health Statistics, sourced through the National Vital Statistics System and updated on February 20, 2026 using 2024 mortality data via CDC WONDER.

Source: CDC/NCHS FastStats Chronic Liver Disease and Cirrhosis, last reviewed February 20, 2026 (2024 data via CDC WONDER); CDC NCHS Data Brief No. 521, December 2024; NIAAA Surveillance Report #118; CDC WONDER-Based Analysis, Cureus, May 2025

The mortality landscape of liver fibrosis and cirrhosis in America 2026 tells a deeply troubling story, especially when age-disaggregated data is examined. While the overall picture of 52,274 deaths in 2024 is sobering enough on its own, what is particularly alarming is the documented rise in liver disease mortality among younger Americans. The CDC WONDER analysis published in Cureus in May 2025 confirmed that chronic liver disease mortality increased in all subgroups of adults aged 25 to 44 between 2000 and 2020 — a cohort that has traditionally not been considered high-risk for liver-related death. The disproportionate burden on American Indian and Alaska Native men aged 35–44, who record an average of 19.4 deaths per 100,000 — among the highest rates of any demographic group — reflects deep and persistent health disparities that go far beyond individual lifestyle choices and implicate systemic access, economic, and cultural factors. The fact that alcohol-related causes account for 80.9% of cirrhosis deaths in the 25–34 age bracket underscores that for young Americans dying of liver disease, alcohol-associated liver injury — now increasingly recognized as a fibrosis driver comparable to MASLD — is the single dominant pathway.

Liver Fibrosis Statistics by Risk Factor & Cause in the US 2026

Liver fibrosis in the United States 2026 does not arise from a single cause. It sits at the intersection of metabolic disease, alcohol use, viral hepatitis, and other chronic liver conditions. Each pathway carries its own burden and prevalence profile, grounded in NHANES and CDC-affiliated data.

Source: NIH/NIDDK NAFLD/MASLD Definition & Facts (updated October 2025); NHANES 2017–2023 analysis, Hepatology Vol. 82(5), November 2025; NIAAA Surveillance Report #118; NCBI StatPearls (MASLD), August 2025; PMC peer-reviewed COVID-19 era fibrosis study, 2025

The risk factor data for liver fibrosis in the US 2026 reveals how tightly this condition is intertwined with the broader epidemic of metabolic disease that is already straining the American healthcare system. The fact that over 90% of obese Americans develop MASLD — and that 60% of diabetic patients have MASLD — means that liver fibrosis is not an isolated liver problem but rather the downstream hepatic consequence of obesity, insulin resistance, and metabolic syndrome. With obesity rates in the United States continuing to rise, the liver fibrosis pipeline will only grow larger over time. The COVID-19 data introduces another dimension that is still being fully appreciated by clinicians: during the pandemic, excessive alcohol consumption became a measurable and statistically significant driver of clinically significant fibrosis — with drinkers showing nearly double the odds (OR: 2.13) of developing significant liver scarring compared to non-drinkers. The pandemic-era increase in fibrosis prevalence from 10.4% to 12.7% may represent a preview of the long-term chronic liver disease burden that will become fully visible in clinical systems over the next decade.

Liver Fibrosis Symptoms Statistics in the US 2026

One of the most medically consequential aspects of liver fibrosis in America 2026 is how silent the condition is, especially in its earlier stages. Understanding the symptom profile — and critically, the lack thereof — has direct implications for why so many Americans go undiagnosed until fibrosis has reached advanced stages.

Source: NIH/NIDDK (Symptoms & Causes of NAFLD & NASH); NCBI StatPearls — Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), August 2025; EASL-EASD-EASO Clinical Practice Guidelines on MASLD, 2024 (PubMed); CDC

The symptom picture of liver fibrosis in the United States 2026 is dominated by one critical reality: early liver fibrosis is almost entirely asymptomatic. This is not just a minor clinical inconvenience — it is the fundamental reason why millions of Americans carry liver scarring for years without any diagnosis, while the condition advances silently toward the threshold of cirrhosis. By the time symptoms like jaundice, ascites, or hepatic encephalopathy appear, the liver has typically progressed to advanced cirrhosis or decompensated liver disease, dramatically narrowing treatment options and worsening prognosis. Fatigue, the most commonly reported symptom of MASLD-related liver disease, is so non-specific that most patients and even clinicians attribute it to a host of other conditions long before liver disease is considered. This diagnostic delay is one of the driving forces behind the large gap between the 11.3% fibrosis prevalence seen in NHANES population surveys and the far smaller number of people who carry an active liver fibrosis diagnosis in the healthcare system. Closing this gap through proactive screening in high-risk populations — particularly those with diabetes, obesity, and metabolic syndrome — is one of the most important clinical challenges in American hepatology in 2026.

Liver Fibrosis Demographic & Racial Disparity Statistics in the US 2026

The burden of liver fibrosis in the United States 2026 is not shared equally. Multiple federal data sources reveal significant disparities by age, sex, and racial/ethnic group that demand targeted public health attention.

Source: NIAAA Surveillance Report #118 (Liver Cirrhosis Mortality in the United States); CDC WONDER-based Analysis, Cureus, May 2025; NHANES 2017–2023, Hepatology Vol. 82(5), November 2025; CDC MMWR National Vital Statistics System data

The demographic data on liver fibrosis and cirrhosis in America 2026 exposes some of the most striking health inequities in the entire chronic disease landscape. The trajectory for women is particularly alarming: while men still account for the majority of liver disease deaths overall, the rate of increase in women has been dramatically faster. A 106% increase in cirrhosis death rates among White women between 2000 and 2019 is not a small statistical fluctuation — it represents a generational shift in who is dying from liver disease in America, driven largely by rising alcohol consumption among women. For American Indian and Alaska Native men aged 35–44, the average of 19.4 deaths per 100,000 is a mortality rate that reflects not just individual health behaviors but deep structural inequities in access to healthcare, prevalence of alcohol use disorder treatment, and broader social determinants of health. The Hispanic paradox also plays out in liver disease in a complicated way: despite generally lower MASLD rates compared to non-Hispanic White adults in some measures, Mexican-origin and Puerto Rican-origin Hispanics actually carry the highest cirrhosis death rates among all Hispanic subgroups, reflecting the compounding effects of ALD and metabolic risk factors.

Healthcare & Economic Cost of Liver Fibrosis in the US 2026

The financial burden of liver fibrosis and cirrhosis in the United States 2026 is enormous and growing. Data from peer-reviewed health economics studies using federal datasets quantify a cost that rivals — and in acute care settings, exceeds — other major chronic diseases.

Source: ACG — Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis (PubMed 2021); PMC — Comparing the Cost of Cirrhosis to Other Common Chronic Diseases, 2025; Journal of Managed Care & Specialty Pharmacy, June 2024; American Journal of Gastroenterology, 2024; Precedence Research Liver Fibrosis Treatment Market 2025

The economic data on liver fibrosis in America 2026 paints a picture of a condition whose true cost is still being underestimated at the policy level. The $32.5 billion baseline from 2016 cirrhosis-related spending — which has been growing at 4.3% annually — has almost certainly crossed $40–45 billion in today’s dollars, and that figure does not include the full upstream cost of managing MASLD and early fibrosis stages before they progress to cirrhosis. The finding that decompensated cirrhosis costs exceed heart failure by 45.5% per patient-month is a critical comparison that healthcare economists and payers need to internalize — liver disease may be less prominently discussed than cardiovascular disease in public health campaigns, but its acute care cost intensity is actually higher. The projection that alcohol-associated liver disease alone will cost $66 billion per year by 2040 — driven by the rise in decompensated cirrhosis costs — represents a preventable financial catastrophe if public health interventions targeting alcohol use disorder are not substantially scaled up. The fact that over 65% of all CLD-related spending is in inpatient and emergency department settings tells you exactly what is happening: patients are being discovered late, when their disease has already reached a crisis point that requires expensive hospitalization, rather than being caught early and managed cost-effectively in outpatient settings.

Liver Fibrosis Treatment Options in the US 2026

The treatment landscape for liver fibrosis in the United States 2026 has seen its most important milestone in decades: the FDA approval of resmetirom (Rezdiffra™) in March 2024, the first drug ever approved specifically for non-cirrhotic MASH with moderate-to-advanced fibrosis. This has opened a new era in pharmacological management alongside established lifestyle and procedural options.

Source: NIH/NIDDK Treatment for NAFLD & NASH (updated 2025); FDA resmetirom approval March 2024; EASL-EASD-EASO Clinical Practice Guidelines on MASLD, PubMed 2024; PMC Resmetirom review, 2025; StatPearls MASLD, August 2025

The treatment picture for liver fibrosis in America 2026 is genuinely more hopeful than it was just two years ago, primarily because of the landmark FDA approval of resmetirom in March 2024 — the first dedicated pharmacological therapy for MASH-related fibrosis in history. Clinical trial data showed resmetirom achieved significant fibrosis regression in patients with stage F2–F3 fibrosis, and it has quickly become a foundational option in specialist management of non-cirrhotic MASH. However, resmetirom does not negate the critical role of lifestyle modification — NIH/NIDDK guidance continues to emphasize that losing 7%–10% of body weight produces meaningful fibrosis regression in MASLD patients, and that physical activity alone — even without weight loss — improves liver fat content. The most clinically significant development beyond resmetirom has been the emerging evidence base for GLP-1 receptor agonists like semaglutide and tirzepatide, which were already transforming the treatment of obesity and type 2 diabetes and are now showing compelling liver-specific benefits including fibrosis regression. One clinical trial showed semaglutide associated with MASH resolution in 63% of treated patients and fibrosis regression in more than a third — results that are reshaping how hepatologists and primary care physicians approach metabolic liver disease simultaneously with its systemic comorbidities.

Liver Fibrosis Prevention Statistics & Strategies in the US 2026

Preventing liver fibrosis in America 2026 is fundamentally about interrupting the upstream causes — metabolic dysfunction, alcohol misuse, and viral hepatitis — before they accumulate enough liver injury to initiate the scarring process. Prevention evidence comes from NIH/NIDDK clinical guidance, CDC recommendations, and population-level data.

Source: NIH/NIDDK Treatment and Prevention for NAFLD & NASH (updated October 2025); EASL-EASD-EASO Clinical Practice Guidelines on MASLD, PubMed 2024; NIAAA Surveillance Report #118; CDC immunization and hepatitis guidance; NHANES 2017–2023, Hepatology November 2025

The prevention data for liver fibrosis in the United States 2026 points directly at the intersection of lifestyle medicine and proactive healthcare. The two most powerful preventable drivers of liver fibrosis in America — metabolic dysfunction (obesity, diabetes, metabolic syndrome) and excessive alcohol consumption — are both theoretically modifiable at the individual and population level, even if achieving meaningful change at scale has proven extraordinarily difficult. The NIH/NIDDK guidance is clear: even a 3%–5% reduction in body weight produces measurable reduction in liver fat, and weight loss of 7%–10% can meaningfully reduce inflammation and fibrosis. These are achievable thresholds for most people with dedicated lifestyle support, and the emergence of GLP-1 agonists as both metabolic and liver-targeted therapies creates an unprecedented opportunity to address fibrosis prevention and treatment simultaneously in the large population of Americans with obesity and type 2 diabetes. The role of early non-invasive screening using tools like the FIB-4 blood test or FibroScan liver elastography is growing in clinical guidelines precisely because the asymptomatic nature of early fibrosis means that without proactive screening, high-risk individuals will simply never be identified until their disease has progressed to a point where options are far more limited and costs are far higher. Screening the estimated 25–28% of American adults with MASLD for elevated fibrosis risk is the single most scalable intervention available to reduce the downstream liver fibrosis burden in America in 2026 and beyond.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE